Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial.

Shouki BazarbashiAhmed AlzahraniAli AljubranMahmoud ElshenawyAhmed Mostafa GadFatima MaraikiNoura AlzannanTusneem ElhassanAhmed Badran

Published in: The oncologist (2023)

Continuous angiogenesis blockade by adding bevacizumab to the sunitinib on/off regimen for advanced RCC yields significant antitumor activity with manageable increased toxicity.

Keyphrases

renal cell carcinoma
metastatic colorectal cancer
study protocol
endothelial cells
clinical trial
oxidative stress
phase iii
phase ii
randomized controlled trial
metastatic renal cell carcinoma
wound healing